Talaris Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mary Kay Fenton
- Full Time Employees
- 84
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 570 South Preston Street Louisville KY United States of America 40202
- IPO Date
- May 7, 2021
- CIK
- 0001827506
- Website
- talaristx.com
- Similar Companies
- Business
- Talaris Therapeutics, Inc. (NASDAQ: TALS) is a clinical-stage biotechnology company developing novel cell therapies, including its proprietary FCR001 product candidate, to induce immune tolerance and eliminate the need for chronic immunosuppression in organ transplant recipients and patients with autoimmune diseases. FCR001, a personalized allogeneic cell therapy derived from donor hematopoietic stem cells enriched for regulatory T cells, targets living donor kidney transplantation, previously transplanted kidney patients, and severe autoimmune conditions such as diffuse systemic sclerosis (scleroderma); the company previously advanced FCR001 through Phase 3 FREEDOM-1 and FREEDOM-2 trials in kidney transplant settings prior to their discontinuation, while continuing Phase 2 FREEDOM-3 evaluation in scleroderma. Talaris operates in the biotechnology sector serving transplant centers, hospitals, and patients requiring advanced immune modulation therapies, with a focus on the United States market. Founded in 2018 and headquartered in Louisville, Kentucky, with additional operations historically in Boston, Houston, and Nashville, Tennessee, the company maintains in-house cell processing capabilities and has pursued a pipeline-in-a-product strategy centered on its Facilitated Allo-HSCT Therapy platform. In a major strategic shift, Talaris completed a reverse merger with Tourmaline Bio, Inc. in October 2023, resulting in a name change to Tourmaline Bio, Inc. (NASDAQ: TRML), a special cash dividend of approximately $1.51 per share to former Talaris shareholders, and a pivot away from Talaris' cell therapy programs to Tourmaline's anti-IL-6 antibody TOUR006 for immune disorders including thyroid eye disease and atherosclerotic cardiovascular disease. Prior to the merger, Talaris discontinued two FCR001 kidney transplant trials in early 2023 due to slow enrollment, reduced its workforce by one-third, and reallocated resources to scleroderma studies amid a strategic review. The ticker TALS continues to trade post-merger, reflecting the combined entity's ongoing operations as of late 2025.
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
3 Hot Penny Stocks to Watch Before Next Week
„MIR M: Vanguard & Vagabond“ – neues MMORPG von Wemade startet weltweit
Novel Spectrometry Platforms Market, 2022-2035: Need for Automation, Reproducibility and Higher Sensitivity Drives Adoption - ResearchAndMarkets.com
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference